Therapeutic Targeting of the Myofibroblast in Fibrotic Lung Disease - Project One: A Phase IIB Clinical Trial of the Safety and Efficacy of a NOX1/4 Inhibitor in IPF

Grant

Date/time Interval

  • August 1, 2018 - July 31, 2023
  • Total Award Amount

  • 925661.00
  • Direct Costs

  • 667489.00
  • Sponsor Award Id

  • P01HL114470
  • Contributor

  • Cutter, Gary   Investigator  
  • De Andrade, Joao   Investigator  
  • Duncan, Steven   Principal Investigator  
  • Luckhardt, Tracy   Investigator